Vanguard Group Inc. Grows Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Vanguard Group Inc. grew its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 1.2% in the third quarter, Holdings Channel.com reports. The firm owned 5,396,285 shares of the medical instruments supplier’s stock after acquiring an additional 64,367 shares during the quarter. Vanguard Group Inc. owned approximately 0.07% of OraSure Technologies worth $32,000,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its holdings in OraSure Technologies by 421.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 384,439 shares of the medical instruments supplier’s stock valued at $2,280,000 after buying an additional 310,715 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of OraSure Technologies by 3.1% in the third quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after purchasing an additional 5,875 shares during the period. Aviva PLC acquired a new stake in OraSure Technologies during the third quarter worth about $580,000. Charles Schwab Investment Management Inc. raised its stake in OraSure Technologies by 28.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 727,617 shares of the medical instruments supplier’s stock worth $4,315,000 after purchasing an additional 162,462 shares during the period. Finally, AQR Capital Management LLC raised its stake in OraSure Technologies by 118.0% during the third quarter. AQR Capital Management LLC now owns 935,510 shares of the medical instruments supplier’s stock worth $5,548,000 after purchasing an additional 506,312 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Price Performance

Shares of OSUR stock opened at $5.77 on Friday. OraSure Technologies, Inc. has a 1-year low of $4.38 and a 1-year high of $8.45. The firm has a market cap of $441.46 million, a PE ratio of 8.01 and a beta of 0.15. The company has a 50-day moving average of $6.76 and a two-hundred day moving average of $6.84.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The firm had revenue of $75.88 million during the quarter, compared to analysts’ expectations of $74.13 million. During the same quarter last year, the company posted $0.21 EPS. The firm’s quarterly revenue was down 38.3% on a year-over-year basis. Sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Evercore ISI cut their price target on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a report on Thursday, April 4th. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $6.38.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.